Entrada Therapeutics

Company snapshot

Headquartered in Boston’s Seaport community, Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, we are advancing a robust development portfolio of genetic medi

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Entrada Therapeutics. Not investment advice.

• Peer + 0 momentum

  Sarepta Therapeutics

  TA overlap score 29.2

Recent activity

Latest pipeline, patent, and corporate events for Entrada Therapeutics.

1. Jun 8, 2026 Clinical update

   SODIUM CHLORIDE, ENTR-601-45 — Phase 2

2. Jun 8, 2026 Clinical update

   ENTR-601-44, SODIUM CHLORIDE — Phase 2

3. Jun 5, 2026 Clinical update

   ENTR-601-45 — Phase 2

4. Jun 5, 2026 Clinical update

   ENTR-601-44 — Phase 2

5. May 21, 2024 Patent grant

   Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy

View all clinical trial activity →

• What is Entrada Therapeutics?

  Entrada Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker TRDA. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy (DMD). NovaPharmaNews links 4 clinical program(s), 0 drug profile(s),

• Is Entrada Therapeutics publicly traded?

  Yes. Entrada Therapeutics is listed with ticker TRDA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Entrada Therapeutics develop or market?

  We link 4 drug profile(s) where Entrada Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/entrada-therapeutics#company-drugs.

• What are the latest developments for Entrada Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Entrada Therapeutics focus on?

  Entrada Therapeutics focuses on Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy (DMD) based on our analysis of their pipeline programs and drug development activities.